Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

11.28 +0.29 (+2.69%)
Streaming Delayed Price Updated: 12:19 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharm Ord

< Previous 1 2 3 4 5 6 7 8 Next >
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Aurinia Pharma Stock Showing A Potential Reversal Pattern: 4 Key Levels To Watch
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) was trending Tuesday afternoon poss... 
Via Benzinga
Aurinia's Lupkynis Shows Sustained Renal Response Rates In Lupus Nephritis Patients
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in... 
Via Benzinga
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
2 Grossly Undervalued Biotech Stocks That Could Double Your Money
Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt. 
Via The Motley Fool
Exposures COVID-19
Another Tough Day For Markets
The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.” 
Via Talk Markets
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Heavy Global Erosion
It is an everything-down day. Even the news is down because commenters are being careful. 
Via Talk Markets
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
Stocks That Hit 52-Week Lows On Monday
Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT).... 
Via Benzinga
Aurinia Pharma's Stock Gains After Lupkynis Data From Late-Stage Lupus Nephritis Study Published In Lancet
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced that The Lancet published its Phase 3 AURORA 1 study evaluating Lupkynis (voclosporin) in adults with... 
Via Benzinga
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Calm Markets Day
Despite seriously disappointing April jobless numbers, markets are gaining all the same. 
Via Talk Markets
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1... 
Via Benzinga
Cramer Shares His Thoughts On Atkore, Petco And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he prefers American Electric Power Company Inc (NASDAQ: AEP) over Consolidated Edison, Inc. (NYSE: ED). If... 
Via Benzinga
56 Stocks Moving In Friday's Mid-Day Session
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321. Regional Health Properties, Inc. (NYSE: RHE) gained 43% to $21.40 after dropping 23% on Thursday.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Friday's morning session saw 17 companies set new 52-week lows. Key Facts: Beyond Meat (NASDAQ:BYND) was the largest firm on a market cap basis to set a new 52-... 
Via Benzinga
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
32 Stocks Moving in Friday's Pre-Market Session
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results. iBio, Inc. (NYSE:... 
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Crashing Today
Expectations for the biotech's first-quarter sales may have been too high. 
Via The Motley Fool
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 33 companies set new 52-week lows. Highlights: The largest company by market cap to set a new 52-week low was iQIYI (NASDAQ:IQ).... 
Via Benzinga
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.